Results 241 to 250 of about 211,802 (307)

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy   +3 more
wiley   +1 more source

A Stacked Ensemble Multi‐Label Model for Predicting Co‐Occurring Microvascular and Macrovascular Complications in Type 2 Diabetes

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Feature importance for predicting multiple diabetes complications based on a Stacking‐Classifier Chain model. Abstract Background Type 2 diabetes mellitus (T2DM) leads to severe microvascular and macrovascular complications. Traditional single‐label prediction models fail to capture their co‐occurring nature.
Maryam Zamani   +3 more
wiley   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

open access: yesChemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart   +7 more
wiley   +1 more source

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial.
Tim Rowland   +48 more
wiley   +1 more source

Chronic Renal Insufficiency

Pediatric Clinics of North America, 1976
Among the clinical disturbances attending chronic renal disease are water and electrolyte imbalances, acidosis, anemia, the toxicity arising from retention of wastes, and growth impairment. The pathogenesis of these abnormalities is discussed along with approaches to their management.
P R, Lewy, J K, Hurley
openaire   +4 more sources

Exophthalmus in Chronic Renal Insufficiency

Scandinavian Journal of Urology and Nephrology, 1971
The present results show that exophthalmus is a common symptom in chronic renal insufficiency. Thus, contrary to the norm, 19 (67%) of 28 clinically euthyroid, chronic dialysis patients displayed increased Hertel values. Tests of thyroid function in these patients indicated a reduced thyroxine-binding capacity of the serum protein and, in some cases, a
P, Schmidt   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy